Brevinin-2R
General Information
DCTPep ID DCTPep00196
Peptide Name Brevinin-2R
Sequence KLKNFAIGVAQSLLNKASCKLSGQC
Sequence Length 25
UniProt ID P85095
PubChem CID Not available
Origin Pelophylax ridibundus (Marsh frog) (Rana ridibunda)
Type Native peptide
Classification
ACP Tumor active peptide
Activity Information
Cell Line | Disease | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|
MCF-7 | Invasive breast carcinoma of no special type | LD50=10-15μg/ml | MTT assay | 4h | 1 |
Jurkat | Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia | LD50=20-25μg/ml | MTT assay | 4h | 1 |
BJAB | Burkitt lymphoma | LD50=30-40μg/ml | MTT assay | 4h | 1 |
Hemolytic Activity Sheep erythrocytes(2.5% hemolytic activity at 200 μg/ml)
Normal (non-cancerous) Cytotoxicity L929: LD50=20-25μg/ml
Target Not available
Affinity Not available
Mechanism Not available
Structure Information
PDB ID Not available
Predicted Structure DCTPep00196
(Please note that there is the predicted structure, predicted by AlphaFold)
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Not available
C-terminal Modification Not available
Other Modification None
Chiral L
Physicochemical Information
Formula C114H197N33O33S2
Absent amino acids DEHMPRTWY
Theoretical pI 9.70
Acidic residues 0
Basic residues 4
Polar residues 9
Molecular weight (Average) 2622.14
Molecular weight (Monoisotopic) 2620.42
Common amino acids KL
Net charge 4
Instability index (II) 30.47
Aliphatic index 101.60
Grand average of hydropathicity (GRAVY) 0.172
Half Life
1.3 hours (mammalian reticulocytes, in vitro).
3 min (yeast, in vivo).
3 min (Escherichia coli, in vivo).
Extinction coefficients
Ext. coefficient 125
Abs 0.1% (=1 g/l) 0.048, assuming all pairs of Cys residues form cystines
Ext. coefficient 0
Abs 0.1% (=1 g/l) 0.000, assuming all Cys residues are reduced
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 18494941
Title Brevinin-2R(1) semi-selectively kills cancer cells by a distinct mechanism, which involves the lysosomal-mitochondrial death pathway
Doi 10.1111/j.1582-4934.2008.00129.x
Year 2008
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available